Drug intelligence / Profile preview

measles vaccine (live)

Development stage
Unknown
Lead developer
GSK
Modality
Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular
01

Overview

The measles virus, Edmonston-Schwarz strain (live, attenuated) is a viral vaccine used to induce active immunity against measles. Derived from the original Edmonston strain isolated by Enders and Peebles, the Schwarz strain was further attenuated through multiple passages in chick embryo cells to reduce pathogenicity while maintaining immunogenicity. Developed and manufactured by GSK Biologicals, it is available as a monovalent vaccine under the brand name Rimevax and serves as the measles component in multivalent vaccines such as Priorix (MMR) and Priorix-Tetra (MMRV). The vaccine works by establishing a limited, non-pathogenic infection in the host, which stimulates a comprehensive immune response including the production of neutralizing antibodies and the activation of T-cells directed against the measles virus hemagglutinin (H) and fusion (F) glycoproteins.

Brand names
Rimevax
Other names
measles virus, edmonston-schwarz strain (live, attenuated)Schwarz strain measles vaccineEdmonston-Schwarz strain measles vaccine
02

Targets

CD46 (CD46 Molecule)SLAMF1 (SLAM family member 1)

Beyond the preview

Go deeper on measles vaccine (live).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles vaccine (live).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call